바이오에프디엔씨

251120KOSDAQ기초 의약물질 제조업

59.5 / 100

Reference Date: 2026-06-10

Financial Score33.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Plunged 29.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioFDC specializes in developing and manufacturing effective substances for cosmetics, health foods, and pharmaceuticals using plant cell platform technology, leveraging gene editing and high-frequency processing techniques for a unique cultivation platform. Key products include plant cell extracts and growth factor-based cosmetic ingredients, with plans to commercialize pharmaceuticals in the medium to long term.

Number of Employees

78people

Average Salary

55.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.05Industry Average 27.718.0Point

Half of industry avg (excellent)

PBR

1.17Industry Average 1.745.5Point

Lower than industry avg (good)

ROE

10.03Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

0.35Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Neutral
"中企정책, 지원보다 성장에 무게 둔다"
정부의 중소기업 지원 정책이 성장 촉진에 초점을 맞추고 있으나, 바이오에프디엔씨의 직접적인 영향은 제한적입니다.
Neutral
유망 중기업 100개, 중견기업행 사다리 놓는다
정부의 점프업 프로그램 선정이 다양한 중소기업 지원을 확대하나, 바이오에프디엔씨의 직접적인 영향은 제한적임.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 9,420Won52-week high 22,25052-week low 9,420

1-month return0.0Point

1m -29.44% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-13